Triggering TLR7 in mice induces immune activation and lymphoid system disruption, resembling HIV-mediated pathology

Blood

Volumn 113, Issue 2, 2009, Pages 377-388

  Baenziger, Stefan ^a   Heikenwalder, Mathias ^b   Johansen, Pål ^c   Schlaepfer, Erika ^a   Hofer, Ursula ^a   Miller, Regina C ^a   Diemand, Simone ^a   Honda, Kenya ^d   Kundig, Thomas M ^c   Aguzzi, Adriano ^b   Speck, Roberto F ^a,e  

^a Hospital Epidemiology   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d UNIVERSITY OF TOKYO   (Japan)

^e UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CYTOKINE; OLIGONUCLEOTIDE; SINGLE STRANDED RNA; TOLL LIKE RECEPTOR 7; URIDINE; IMIDAZOLE DERIVATIVE; IMMUNOGLOBULIN G; MEMBRANE PROTEIN; RESIQUIMOD; TLR7 PROTEIN, MOUSE; TOLL LIKE RECEPTOR 8; VIRUS RNA;

ANTIBODY PRODUCTION; ARTICLE; B LYMPHOCYTE; DISEASE COURSE; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE DEFICIENCY; IMMUNITY; IMMUNOPATHOLOGY; LYMPHATIC SYSTEM; LYMPHATIC SYSTEM DISEASE; LYMPHOCYTOPENIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN LYMPHOCYTE; SPLENOMEGALY; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL; DRUG EFFECT; DRUG POTENTIATION; FEMALE; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; MALE; MOUSE MUTANT; PATHOLOGY; SIGNAL TRANSDUCTION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANIMALS; ANTIBODY FORMATION; B-LYMPHOCYTES; FEMALE; HIV-1; HUMANS; IMIDAZOLES; IMMUNOGLOBULIN G; MALE; MEMBRANE GLYCOPROTEINS; MICE; MICE, KNOCKOUT; RNA, VIRAL; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 7; TOLL-LIKE RECEPTOR 8;

EID: 58849119199     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-04-151712     Document Type: Article

References (58)

1. Langford SE, Ananworanich J, Cooper DA. Predictors of disease progression in HIV infection: a review. AIDS ResTher. 2007;4:11.
2. Silvestri G, Sodora DL, Koup RA, et al. Nonpathogenic SIV infection of sooty mangabeys is characterized by limited bystander immunopathology despite chronic high-level viremia. Immunity. 2003;18:441-452.
3. Wu L, Paxton WA, Kassam N, et al. CCR5 levels and expression pattern correlate with infectability by macrophage-tropic HIV-1, in vitro. J Exp Med. 1997;185:1681-1691.
4. Kang SM,TranAC, Grilli M, LenardoMJ. NF-kappa B subunit regulation in nontransformed CD4+ T lymphocytes. Science. 1992;256:1452-1456.
5. Shattock RJ, Rizzardi GP, Hayes P, Griffin GE. Engagement of adhesion molecules (CD18, CD11a, CD45, CD44, and CD58) enhances human immunodeficiency virus type 1 replication in monocytic cells through a tumor necrosis factor-modulated pathway. J Infect Dis. 1996;174:54-62.
6. Tesselaar K, Arens R, van Schijndel GM, et al. Lethal T cell immunodeficiency induced by chronic costimulation via CD27-CD70 interactions. Nat Immunol. 2003;4:49-54.
7. Schindler M, Munch J, Kutsch O, et al. Nef-mediated suppression of T cell activation was lost in a lentiviral lineage that gave rise to HIV-1. Cell. 2006;125:1055-1067.
8. Smith SM. The pathogenesis of HIV infection: stupid may not be so dumb after all. Retrovirology. 2006;3:60.
9. Swingler S, Mann A, Jacque J, et al. HIV-1 Nef mediates lymphocyte chemotaxis and activation by infected macrophages. Nat Med. 1999;5:997-103.
10. Cicala C, Arthos J, Selig SM, et al. HIV envelope induces a cascade of cell signals in non-proliferating target cells that favor virus replication. Proc Natl Acad Sci USA. 2002;99:9380-9385.
11. Eggena MP, Barugahare B, Jones N, et al. Depletion of regulatory T cells in HIV infection is associated with immune activation. J Immunol. 2005; 174:4407-4414.
12. Takeda K, KaishoT, Akira S. Toll-like receptors. Annu Rev Immunol. 2003;21:335-376.
13. Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med. 2006;12:1365-1371.
14. Meier A, Alter G, Frahm N, et al. MyD88-dependent immune activation mediated by human immunodeficiency virus type 1-encoded toll-like receptor ligands. J Virol. 2007;81:8180-8191.
15. Heil F, Hemmi H, Hochrein H, et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science. 2004;303:1526-1529.
16. Beignon AS, McKenna K, Skoberne M, et al. Endocytosis of HIV-1 activates plasmacytoid dendritic cells via Toll-like receptor-viral RNA interactions. J Clin Invest. 2005;115:3265-3275.
17. Lester RT, Yao XD, Ball TB, et al. Toll-like receptor expression and responsiveness are increased in viraemic HIV-1 infection. Aids. 2008;22:685-694.
18. Funderburg N, Luciano AA, Jiang W, Rodriguez B, Sieg SF, Lederman MM. Toll-Like Receptor Ligands Induce Human T Cell Activation and Death, a Model for HIV Pathogenesis. PLoS ONE. 2008;3:e1915.
19. Schlaepfer E, Audige A, Joller H, Speck RF TLR7/8 triggering exerts opposing effects in acute versus latent HIV infection. J Immunol. 2006;176:2888-2895.
20. Diebold SS. Recognition of viral single-stranded RNA by Toll-like receptors. Adv Drug Deliv Rev. 2008;60:813-823.
21. Gorden KK, Qiu XX, Binsfeld CC, Vasilakos JP, Alkan SS. Cutting edge: activation of murine TLR8 by a combination of imidazoquinoline immune response modifiers and polyT oligode-oxynucleotides. J Immunol. 2006;177:6584-6587.
22. Muller U, Steinhoff U, Reis LF, et al. Functional role of type I and type II interferons in antiviral defense. Science. 1994;264:1918-1921.
23. Hemmi H, KaishoT, Takeuchi O, et al. Small antiviral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol. 2002;3:196-200.
24. Honda K, Yanai H, Negishi H, et al. IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature. 2005;434:772-777.
25. Adachi O, Kawai T, Takeda K, et al. Targeted disruption of the MyD88 gene results in loss of IL-1-and IL-18-mediated function. Immunity. 1998;9: 143-150.
26. Bachmann MF, Odermatt B, Hengartner H, Zinkernagel RM. Induction of long-lived germinal centers associated with persisting antigen after viral infection. J Exp Med. 1996;183:2259-2269.
27. Karrer U, Lopez-Macias C, Oxenius A, et al. Antiviral B cell memory in the absence of mature follicular dendritic cell networks and classical germinal centers in TNFR1 -/- mice. J Immunol. 2000; 164:768-778.
28. Fieller EC. Suppl to JR Statist Soc. 1941;7:1-64.
29. Gunzer M, Riemann H, Basoglu Y, et al. Systemic administration of a TLR7 ligand leads to transient immune incompetence due to peripheral-blood leukocyte depletion. Blood. 2005;106:2424-2432.
30. Kaslow RA, PhairJP, Friedman HB, etal. Infection with the human immunodeficiency virus: clinical manifestations and their relationship to immune deficiency. A report from the Multicenter AIDS Cohort Study.Ann Intern Med. 1987;107:474-480.
31. De Milito A, Nilsson A, Titanji K, et al. Mechanisms of hypergammaglobulinemia and impaired antigen-specific humoral immunity in HIV-1 infection. Blood. 2004;103:2180-2186.
32. Taylor PR, Martinez-Pomares L, Stacey M, Lin HH, Brown GD, Gordon S. Macrophage receptors and immune recognition. Annu Rev Immunol. 2005;23:901-944.
33. Kranich J, Krautler NJ, Heinen E, et al. Follicular dendritic cells control engulfment of apoptotic bodies by secreting Mfge8. J Exp Med. 2008;205: 1293-1302.
34. Furrer H. Prevalence and clinical significance of splenomegaly in asymptomatic human immunodeficiency virus type 1-infected adults. Swiss HIV cohort study. Clin Infect Dis. 2000;30:943-945.
35. Norris PJ, Pappalardo BL, Custer B, Spotts G, Hecht FM, Busch MP. Elevations in IL-10, TNF-alpha, and IFN-gamma from the earliest point of HIV Type 1 infection. AIDS Res Hum Retroviruses. 2006;22:757-762.
36. Ye P, Kirschner DE, Kourtis AP. The thymus during HIV disease: role in pathogenesis and in immune recovery. Curr HIV Res. 2004;2:177-183.
37. Geskus RB, Prins M, Hubert JB, et al. The HIV RNA setpoint theory revisited. Retrovirology. 2007;4:65.
38. Ballem PJ, Belzberg A, Devine DV, et al. Kinetic studies of the mechanism of thrombocytopenia in patients with human immunodeficiency virus infection. N Engl J Med. 1992;327:1779-1784.
39. Tacchini-Cottier F, Vesin C, Redard M, Buurman W, Piguet PF. Role of TNFR1 and TNFR2 in TNF-induced platelet consumption in mice. J Immunol. 1998;160:6182-6186.
40. Kamphuis E, Junt T, Waibler Z, Forster R, Kalinke U. Type I interferons directly regulate lymphocyte recirculation and cause transient blood lymphopenia. Blood. 2006.
41. Fransen F, Boog CJ, van Putten JP, van der Ley P. Agonists of Toll-like receptor 3, 4, 7, and 9 are adjuvant candidates for use in an outer membrane vaccine against Neisseria meningitidis serogroup B. Infect Immun. 2007.
42. Bishop GA, Ramirez LM, Baccam M, Busch LK, Pederson LK, Tomai MA. The immune response modifier resiquimod mimics CD40-induced B cell activation. Cell Immunol. 2001;208:9-17.
43. Bernstein DI, Harrison CJ, Tomai MA, Miller RL. Daily or weekly therapy with resiquimod (R-848) reduces genital recurrences in herpes simplex virus-infected guinea pigs during and after treatment. J Infect Dis. 2001;183:844-849.
44. Pantaleo G, Graziosi C, Demarest JF, et al. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature. 1993;362:355-358.
45. Cohen OJ, Pantaleo G, Lam GK, Fauci AS. Studies on lymphoid tissue from HIV-infected individuals: implications for the design of therapeutic strategies. Springer Semin Immunopathol. 1997; 18:305-322.
46. Subramanian S, Tus K, Li QZ, et al. A Tlr7 trans-location accelerates systemic autoimmunity in murine lupus. Proc Natl Acad Sci U SA. 2006; 103:9970-9975.
47. Brooks DG, Trifilo MJ, Edelmann KH, Teyton L, McGavern DB, Oldstone MB. Interleukin-10 determines viral clearance or persistence in vivo. Nat Med. 2006;12:1301-1309.
48. Ejrnaes M, Filippi CM, Martinic MM, et al. Resolution of a chronic viral infection after interleukin-10 receptor blockade. J Exp Med. 2006;203:2461-2472.
49. Shin HD, Winkler C, Stephens JC, et al. Genetic restriction of HIV-1 pathogenesis to AIDS by promoter alleles of IL10. Proc Natl Acad Sci USA. 2000;97:14467-14472.
50. Accapezzato D, Francavilla V, Paroli M, et al. Hepatic expansion of a virus-specific regulatory CD8(+) Tcell population in chronic hepatitis C virus infection. J Clin Invest. 2004;113:963-972.
51. Rosenberg ZF, Fauci AS. Immunopathogenic mechanisms of HIV infection: cytokine induction of HIV expression. ImmunolToday. 1990;11:176-180.
52. Glosli H, Prydz H, Roald B. Involution of thymus and lymphoid depletion in mice expressing the hTNFtransgene. Apmis. 2004;112:63-73.
53. Chun TW, Carruth L, Finzi D, et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature. 1997;387:183-188.
54. Haase AT, Henry K, Zupancic M, et al. Quantitative image analysis of HIV-1 infection in lymphoid tissue. Science. 1996;274:985-989.
55. Schon MP, Schon M, Klotz KN. The small antitumoral immune response modifier imiquimod interacts with adenosine receptor signaling in a TLR7- and TLR8-independent fashion. J Invest Dermatol. 2006;126:1338-1347.
56. Schon MP, Schon M. TLR7 and TLR8 as targets in cancer therapy. Oncogene. 2008;27: 190-199.
57. Trinchieri G, Sher A. Cooperation of Toll-like receptor signals in innate immune defence. Nat Rev Immunol. 2007;7:179-190.
58. Reiter MJ, Testerman TL, Miller RL, Weeks CE, Tomai MA. Cytokine induction in mice by the immunomodulator imiquimod. J Leukoc Biol. 1994; 55:234-240.